FDA approved AbbVie’s once-daily pill Juvmo (tavapadon) on Sept. 25 for early and later-stage Parkinson’s, expected in U.S. pharmacies in October 2026.
FDA Approves Once Daily Parkinson’s Pill For Treating Symptoms
Browsing Category
Medication & Medical Management
170 posts
Diabetes Study Finds Keeping Blood Sugar Too Steady May Come At A Price
A 400-person study found more time in range and greater glucose variability were each associated with better next-day quality of life.
Is AI Coming To The Medicare Annual Wellness Visit?
CMS is seeking input on whether clinical AI could support Medicare wellness visits, while keeping care tied to Medicare-enrolled providers.
Glucosamine, A Popular Joint Supplement, Linked To Faster Alzheimer’s Progression
A University of Florida study found an association between glucosamine use and MCI progression, but it does not show the supplement causes dementia.
Did FDA Advisors Support A Cancer Early-Detection Blood Test?
Interest is rising in a question about FDA advisors and a cancer blood test, but the available source does not confirm a meeting or decision.
#Medicare Trending In The Fediverse
Medicare-related topics are trending on Mastodon with increased activity, though the cause remains unconfirmed. This signals rising online interest in healthcare discussions.
Back And Shoulder Surgery Is Often Worse Than Useless
Emerging analysis suggests many back and shoulder surgeries may be more harmful than beneficial, raising concerns about current surgical practices.
Short Steroid Bursts Tied To Serious Adverse Events In Diabetes
Emerging data suggests brief steroid treatments may increase severe adverse events among diabetes patients, raising safety concerns amid rising coverage interest.
Adial Pharmaceuticals Surges In Global Coverage
Adial Pharmaceuticals experiences a surge in worldwide coverage, with search interest spiking 13 times above baseline, amid rising industry attention.
Celldex Therapeutics Surges In Global Coverage
Search interest in Celldex Therapeutics has spiked, with 18 mentions this window, indicating rising global attention on the biotech firm.
